Format

Send to

Choose Destination
J Radiosurg SBRT. 2016;4(2):97-106.

Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery.

Author information

1
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06510, USA.
2
Department of Internal Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT 06510, USA.
3
Yale School of Medicine, New Haven, CT 06510, USA.
4
Department of Neurosurgery, Yale School of Medicine, New Haven, CT 06510, USA.

Abstract

Background:

Metastatic melanoma often involves the brain. Radiotherapy is an important treatment of melanoma brain metastases, although melanoma radiosensitivity is considered heterogeneous. Thus, identifying subsets with differential radiosensitivity is essential.

Materials and Methods:

Patients with metastatic melanoma were identified in a prospective stereotactic radiosurgery (SRS) database. Tumor were tested for alterations in B-RAF, N-RAS, and c-KIT. Standardized imaging following SRS was reviewed for recurrence. Differences in local and distant failure were determined using modified Cox proportional hazards models.

Results:

102 patients and 1,028 brain metastases were included. N-RAS mutated patients were significantly less likely to develop local recurrence after SRS than wild type patients (HR 0.17, 95% CI 0.04-0.72, p=0.017). B-RAF and c-KIT mutations were not associated with altered rates of local recurrence. Lower local recurrence rates for N-RAS mutated tumors persisted on multivariate analysis (HR 0.18, 95% CI 0.04-0.84p=0.029).

Conclusions:

N-RAS mutation is associated with improved local control following SRS. Local recurrence is more common in wild type patients and those with B-RAF or c-KIT mutations. Further research is needed to validate these findings and integrate into practice.

KEYWORDS:

BRAF; NRAS; melanoma; radiosensitivity; radiosurgery

PMID:
29296434
PMCID:
PMC5658871

Conflict of interest statement

Authors’ disclosure of potential conflicts of interest Dr. Rutter reports personal fees from Elekta AB, outside the submitted work. Dr. Yu reports grants from the PhRMA Foundation, grants from 21st Century Oncology, outside the submitted work. Dr. Bindra. Dr. Chiang, Dr. Contessa, Dr. Jilaveanu, Dr. Johung, Dr. Kluger, Mr. Lu, and Dr. Yao have nothing to disclose.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center